Terrie Curran's most recent trade in Arcutis Biotherapeutics Inc was a trade of 27,052 Stock Option (right to buy) done . Disclosure was reported to the exchange on Aug. 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2026 | 27,052 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Sale of securities on an exchange or to another person at price $ 25.03 per share. | 27 Aug 2026 | 27,052 | 23,526 (0%) | 0% | 25.0 | 677,095 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.63 per share. | 27 Aug 2026 | 27,052 | 50,578 (0%) | 0% | 8.6 | 233,459 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.51 per share. | 27 Aug 2026 | 11,148 | 34,674 (0%) | 0% | 7.5 | 83,721 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2026 | 11,148 | 0 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Sale of securities on an exchange or to another person at price $ 25.03 per share. | 27 Aug 2026 | 11,148 | 23,526 (0%) | 0% | 25.0 | 279,028 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.51 per share. | 20 Aug 2026 | 1,072 | 24,598 (0%) | 0% | 7.5 | 8,051 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2026 | 1,072 | 11,148 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Sale of securities on an exchange or to another person at price $ 26.04 per share. | 20 Aug 2026 | 1,072 | 23,526 (0%) | 0% | 26.0 | 27,912 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2026 | 16,667 | 16,667 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2026 | 5,778 | 23,526 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 20,568 | 20,568 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 7,609 | 17,748 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 342,500 | 342,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | Sale of securities on an exchange or to another person at price $ 6.59 per share. | 21 Jan 2025 | 19,109 | 360,465 (1%) | 0% | 6.6 | 125,884 | Common Stock |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Sale of securities on an exchange or to another person at price $ 10.85 per share. | 11 Nov 2024 | 8,687 | 10,139 (0%) | 0% | 10.8 | 94,238 | Common Stock |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 15 Jul 2024 | 33,848 | 377,734 (1%) | 0% | 11.7 | 396,699 | Common Stock | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 27,052 | 27,052 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 10,139 | 18,826 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 22 Mar 2024 | 16,851 | 410,784 (1%) | 0% | 9.1 | 153,513 | Common Stock | |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 18 Jan 2024 | 475,000 | 475,000 | - | - | Stock Option (Right to Buy) | ||
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 14 Jul 2023 | 225,000 | 0 | - | - | Stock Option | ||
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 14 Jul 2023 | 200,000 | 389,671 (1%) | 0% | - | Common Stock | ||
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 14 Jul 2023 | 175,000 | 0 | - | - | Stock Option | ||
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 12,220 | 12,220 | - | - | Stock Option (right to buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 4,375 | 8,687 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 06 Apr 2023 | 12,919 | 188,290 (0%) | 0% | 7.8 | 101,025 | Common Stock | |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 01 Mar 2023 | 1,436 | 175,371 (0%) | 0% | 8.5 | 12,265 | Common Stock | |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 19 Jan 2023 | 162,500 | 162,500 | - | - | Stock Option (Right to Buy) | ||
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 19 Jan 2023 | 97,500 | 182,628 (0%) | 0% | 0 | Common Stock | ||
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 19 Jan 2023 | 5,821 | 176,807 (0%) | 0% | 8.2 | 47,729 | Common Stock | |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 21 Nov 2022 | 1,526 | 83,720 (0%) | 0% | 9.6 | 14,650 | Common Stock | |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 01 Sep 2022 | 7,500 | 85,246 (0%) | 0% | 0 | Common Stock | ||
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 11,796 | 11,796 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Terrie Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 4,312 | 4,312 (0%) | 0% | 0 | Common Stock | |
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 19 May 2022 | 12,000 | 76,595 (0%) | 0% | 0 | Common Stock | ||
| Phathom Pharma Inc | Terrie Curran | Director, President and Chief Executive | 13 May 2022 | 20,500 | 64,595 (0%) | 0% | 7.4 | 151,835 | Common Stock |